Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma

Table 4 Results of overall response rate and disease control rate analysis

Author	Year	Overall response rate (%)			Disease control rate (%)
		AFP responders	AFP nonresponders	RR1	AFP responders	AFP nonresponders	RR1
Chen et al[21]	2005	-	-	-	-	-	-
Chan et al[20]	2009	46.8	7.1	0.57	91.5	41.4	0.15
Riaz et al[27]	2009	43.5	31.6	0.61	91.3	68.4	0.22
Vora et al[29]	2009	25.0	10.0	0.83	93.8	56.7	0.14
Shao et al[28]	2010	33.0	8.0	0.73	83.0	35.0	0.26
Kim et al[23]	2011	44.5	12.5	0.63	87.1	58.3	0.50
Yau et al[30]	2011	-	-	-	-	-	-
Kao et al[22]	2012	-	-	-	-	-	-
Lee et al[24]	2012/H	36.0	8.6	0.70	64.0	45.7	0.66
Lee et al[24]	2012/C	36.5	20.0	0.79	80.8	66.7	0.58
Memon et al[25]	2012	36.7	7.7	0.69	-	-	-
Personeni et al[26]	2012	-	-	-	-	-	-

¹Calculated result from data presented in article; 2012/H: Hepatic arterial infusional chemotherapy study; 2012/C: Concurrent chemoradiation therapy study; -: Not performed; AFP: α-fetoprotein; RR: Relative risk.